Asset Details
Do you wish to reserve the book?
Beta-adrenoceptor drugs and progression to Parkinson’s disease milestones in a large pooled incident cohort
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Beta-adrenoceptor drugs and progression to Parkinson’s disease milestones in a large pooled incident cohort
Do you wish to request the book?
Beta-adrenoceptor drugs and progression to Parkinson’s disease milestones in a large pooled incident cohort
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Beta-adrenoceptor drugs and progression to Parkinson’s disease milestones in a large pooled incident cohort
2025
Overview
Beta-adrenoceptor-blockers and agonists have been associated with an increased and decreased risk of Parkinson’s disease (PD), respectively. We aimed to investigate whether these medications are linked to clinical heterogeneity and progression in PD. Longitudinal data from the Parkinson’s Incident Cohorts Collaboration (
n
= 1107) were analysed. Baseline clinical status and progression to Hoehn & Yahr stage 3 (H&Y3) or dementia were compared in beta-blocker or beta-agonist users versus non-users of each drug. Baseline motor and cognitive variables were similar in beta-blocker users (
n
= 195) versus non-users and beta-agonist users (
n
= 68) versus non-users, following adjustment for relevant confounders. Beta-blocker users (
n
= 156) progressed faster to H&Y3 (
p
= 0.002), accounting for relevant confounders (Hazard Ratio (HR) = 1.538;
p
= 0.011), while beta-agonist users (
n
= 54) progressed similarly to non-users. Neither drug was associated with progression to dementia. These findings support the possibility that beta-adrenoceptor drugs may have potential in modifying aspects of PD progression. Further investigation is essential to identify any causative component in the relationship.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
